Latest news with #GreenhavenRoadCapital
Yahoo
23-05-2025
- Business
- Yahoo
What's Powering PAR Technology's (PAR) Growth and Profitability?
Greenhaven Road Capital, an investment management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund returned around -12% net of fees and expenses, trailing the Russell 2000 by approximately 2% in large part. The Q1 letter focused on President Trump's Liberation Day and the attendant tariff policies rather than company fundamentals. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first-quarter 2025 investor letter, Greenhaven Road Capital highlighted stocks such as PAR Technology Corporation (NYSE:PAR). PAR Technology Corporation (NYSE:PAR) offers omnichannel cloud-based hardware and software solutions to the restaurant and retail industries. The one-month return of PAR Technology Corporation (NYSE:PAR) was 11.65%, and its shares gained 38.49% of their value over the last 52 weeks. On May 22, 2025, PAR Technology Corporation (NYSE:PAR) stock closed at $66.39 per share with a market capitalization of $2.689 billion. Greenhaven Road Capital stated the following regarding PAR Technology Corporation (NYSE:PAR) in its Q1 2025 investor letter: "PAR Technology Corporation (NYSE:PAR) – PAR does have a legacy hardware business that would be impacted by tariffs. PAR's supply chains primarily involve South Korea and Taiwan, so they should not be impacted by the super-sized China tariffs, and the company believes that tariff costs generally can be passed on to customers. That said, virtually nobody owns PAR for the hardware business, though it is helpful to be vertically integrated and subsidized hardware can be used to secure very high-margin software contracts. I cannot imagine an informed PAR investor selling their shares because of the impact of tariffs. Further, PAR's core customers are Quick Service Restaurants (Burger King, etc.), which generally do very well in a weaker economy as consumers 'trade down.' An engineer working in a tech lab, surrounded by tools and components. PAR Technology Corporation (NYSE:PAR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 33 hedge fund portfolios held PAR Technology Corporation (NYSE:PAR) at the end of the fourth quarter compared to 24 in the third quarter. PAR Technology Corporation's (NYSE:PAR) first quarter revenue increased more than 48% to $104 million. While we acknowledge the potential of PAR Technology Corporation (NYSE:PAR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered PAR Technology Corporation (NYSE:PAR) and shared Greenhaven Road Capital's views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
22-05-2025
- Business
- Yahoo
Is Burford Capital (BUR) Resilient to Tariffs?
Greenhaven Road Capital, an investment management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund returned around -12% net of fees and expenses, trailing the Russell 2000 by approximately 2% in large part. The Q1 letter focused on President Trump's Liberation Day and the attendant tariff policies rather than company fundamentals. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first-quarter 2025 investor letter, Greenhaven Road Capital highlighted stocks such as Burford Capital Limited (NYSE:BUR). Burford Capital Limited (NYSE:BUR) offers legal finance products and services. The one-month return of Burford Capital Limited (NYSE:BUR) was -4.99%, and its shares lost 5.54% of their value over the last 52 weeks. On May 21, 2025, Burford Capital Limited (NYSE:BUR) stock closed at $13.12 per share with a market capitalization of $2.87 billion. Greenhaven Road Capital stated the following regarding Burford Capital Limited (NYSE:BUR) in its Q1 2025 investor letter: "Burford Capital Limited (NYSE:BUR) – Burford finances litigation and there are virtually no tariff impacts on the company. During economic downturns, companies are typically more likely to turn to external financing for their litigation. We attended Burford's recent investor day, which happened to be the day following 'Liberation Day' (link to slides), and management agreed that the tariffs should not impact their core business. An accountant meticulously going over documents in her office, exemplifying the company's commitment to accuracy and detail. Burford Capital Limited (NYSE:BUR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 30 hedge fund portfolios held Burford Capital Limited (NYSE:BUR) at the end of the fourth quarter compared to 22 in the third quarter. While we acknowledge the potential of Burford Capital Limited (NYSE:BUR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Burford Capital Limited (NYSE:BUR) and shared the list of best undervalued UK stocks to buy. In its Q4 2024 investor letter, Greenhaven Road Capital emphasized the likelihood of settlement in the ongoing lawsuit, which, if settled, could enhance Burford's long-term growth prospects. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
22-05-2025
- Business
- Yahoo
What Makes Lifecore Biomedical (LFCR) a Beneficiary of the Trade Policies?
Greenhaven Road Capital, an investment management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund returned around -12% net of fees and expenses, trailing the Russell 2000 by approximately 2% in large part. The Q1 letter focused on President Trump's Liberation Day and the attendant tariff policies rather than company fundamentals. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first-quarter 2025 investor letter, Greenhaven Road Capital highlighted stocks such as Lifecore Biomedical, Inc. (NASDAQ:LFCR). Lifecore Biomedical, Inc. (NASDAQ:LFCR) is an integrated contract development and manufacturing organization. The one-month return of Lifecore Biomedical, Inc. (NASDAQ:LFCR) was 4.46%, and its shares gained 13.27% of their value over the last 52 weeks. On May 21, 2025, Lifecore Biomedical, Inc. (NASDAQ:LFCR) stock closed at $6.45 per share with a market capitalization of $238.628 million. Greenhaven Road Capital stated the following regarding Lifecore Biomedical, Inc. (NASDAQ:LFCR) in its Q1 2025 investor letter: "In April, shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR), an existing holding and domestic CDMO, sold off with the broader market despite their likely beneficiary status. We took advantage of buying opportunities and took our ownership in the company up to just under 10% of the shares outstanding. As previously discussed, Lifecore is a likely beneficiary of the trade policies. Their largest challenge and opportunity is to sell their excess capacity. As domestic capacity is not sufficient to support significant re-shoring, the new policies increase the likelihood that Lifecore fills out its excess capacity while pulling forward the timing and magnitude of profit margin improvement." A village pharmacist fulfilling a patient's medication prescription in a rural area. Lifecore Biomedical, Inc. (NASDAQ:LFCR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held Lifecore Biomedical, Inc. (NASDAQ:LFCR) at the end of the fourth quarter compared to 10 in the third quarter. In the fiscal third quarter of fiscal 2025, Lifecore Biomedical, Inc. (NASDAQ:LFCR) generated $35.2 million in revenues compared to $35.7 million for the comparable 2024 period. While we acknowledge the potential of Lifecore Biomedical, Inc. (NASDAQ:LFCR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Lifecore Biomedical, Inc. (NASDAQ:LFCR) and shared Greenhaven Road Capital's views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
22-05-2025
- Business
- Yahoo
Here are Greenhaven Road Capital's Views on Cellebrite (CLBT
Greenhaven Road Capital, an investment management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund returned around -12% net of fees and expenses, trailing the Russell 2000 by approximately 2% in large part. The Q1 letter focused on President Trump's Liberation Day and the attendant tariff policies rather than company fundamentals. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first-quarter 2025 investor letter, Greenhaven Road Capital highlighted stocks such as Cellebrite DI Ltd. (NASDAQ:CLBT). Headquartered in Petah Tikva, Israel, Cellebrite DI Ltd. (NASDAQ:CLBT) is a software company that develops solutions for legally sanctioned investigations. The one-month return of Cellebrite DI Ltd. (NASDAQ:CLBT) was -14.37%, and its shares gained 40.99% of their value over the last 52 weeks. On May 21, 2025, Cellebrite DI Ltd. (NASDAQ:CLBT) stock closed at $16.89 per share with a market capitalization of $4.009 billion. Greenhaven Road Capital stated the following regarding Cellebrite DI Ltd. (NASDAQ:CLBT) in its Q1 2025 investor letter: "Cellebrite DI Ltd. (NASDAQ:CLBT) – As one of a very small handful of suppliers selling unique software and services critical to law enforcement, there is virtually no risk of Cellebrite being impacted from the tariffs. While there has been some concern about DOGE (Department of Government Efficiency) slashing government contracts, the 20% of Cellebrite's revenues that are related to the federal government mostly address high-profile priorities like securing the border and investigating the legal status of individuals. Cellebrite tools are unlikely to be cut. A female engineer in a datacenter, wearing a headset, monitoring digital data. Cellebrite DI Ltd. (NASDAQ:CLBT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 34 hedge fund portfolios held Cellebrite DI Ltd. (NASDAQ:CLBT) at the end of the fourth quarter compared to 30 in the third quarter. Cellebrite DI Ltd. (NASDAQ:CLBT) reported revenue of $107.5 million in Q1 2025, representing an increase of 20% year-over-year. While we acknowledge the potential of Cellebrite DI Ltd. (NASDAQ:CLBT) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Cellebrite DI Ltd. (NASDAQ:CLBT) and shared Greenhaven Road Capital's views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
What Makes Lifecore Biomedical (LFCR) a Beneficiary of the Trade Policies?
Greenhaven Road Capital, an investment management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund returned around -12% net of fees and expenses, trailing the Russell 2000 by approximately 2% in large part. The Q1 letter focused on President Trump's Liberation Day and the attendant tariff policies rather than company fundamentals. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first-quarter 2025 investor letter, Greenhaven Road Capital highlighted stocks such as Lifecore Biomedical, Inc. (NASDAQ:LFCR). Lifecore Biomedical, Inc. (NASDAQ:LFCR) is an integrated contract development and manufacturing organization. The one-month return of Lifecore Biomedical, Inc. (NASDAQ:LFCR) was 4.46%, and its shares gained 13.27% of their value over the last 52 weeks. On May 21, 2025, Lifecore Biomedical, Inc. (NASDAQ:LFCR) stock closed at $6.45 per share with a market capitalization of $238.628 million. Greenhaven Road Capital stated the following regarding Lifecore Biomedical, Inc. (NASDAQ:LFCR) in its Q1 2025 investor letter: "In April, shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR), an existing holding and domestic CDMO, sold off with the broader market despite their likely beneficiary status. We took advantage of buying opportunities and took our ownership in the company up to just under 10% of the shares outstanding. As previously discussed, Lifecore is a likely beneficiary of the trade policies. Their largest challenge and opportunity is to sell their excess capacity. As domestic capacity is not sufficient to support significant re-shoring, the new policies increase the likelihood that Lifecore fills out its excess capacity while pulling forward the timing and magnitude of profit margin improvement." A village pharmacist fulfilling a patient's medication prescription in a rural area. Lifecore Biomedical, Inc. (NASDAQ:LFCR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held Lifecore Biomedical, Inc. (NASDAQ:LFCR) at the end of the fourth quarter compared to 10 in the third quarter. In the fiscal third quarter of fiscal 2025, Lifecore Biomedical, Inc. (NASDAQ:LFCR) generated $35.2 million in revenues compared to $35.7 million for the comparable 2024 period. While we acknowledge the potential of Lifecore Biomedical, Inc. (NASDAQ:LFCR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Lifecore Biomedical, Inc. (NASDAQ:LFCR) and shared Greenhaven Road Capital's views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
